Article
[Ruxolitinib combined with venetoclax and azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 14 Sept 2024
Xu P P, Zhou T, Xu Y Y, Peng M X, Du Y, Xie T, Yang Y G, Ouyang J, Chen B
Abstract excerpt
Refractory acute T-lymphoblastic leukemia (T-ALL), which is characterized by a low sensitivity to conventional induction therapy and poor prognosis, poses significant challenges during treatment. This study reported a case of refractory T-ALL patient with mutations in the JAK1, JAK3, and STAT5B genes from Nanjing University's Gulou Hospital. Following an unsuccessful course of standard VDLP regimen chemotherapy,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.